Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 19
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Phathom Pharmaceuticals Inc
PHAT
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$6.92
N/A
Dern. MÀJ: Oct 19, 9:28 AM
$6.92
N/A
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Résultats:
Résultats Q3 2026 dans dans 10 jours à partir de maintenant le jeu. oct. 29th, avant l'ouverture du marché
Phathom Pharmaceuticals Financials
Phathom Pharmaceuticals (PHAT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Phathom Pharmaceuticals Q2 Adj. EPS $0.00 Beats $(0.25) Estimate, Sales $74.300M Beat $72.789M Estimate
Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.25) by 100 percent. This is a 100 percent increase over losses of $(0.79) per share
Benzinga Newsdesk
PRO
Phathom Pharmaceuticals Lowers FY2026 Sales Guidance from $320.000M-$345.000M to $310.000M-$325.000M vs $332.196M Est
Phathom Pharmaceuticals (NASDAQ:PHAT) lowers FY2026 sales outlook from $320.000 million-$345.000 million to $310.000 million-$325.000 million vs $332.196 million estimate.
Benzinga Newsdesk
PRO
Phathom Pharmaceuticals Q2 Sales $74.300M Beat $72.789M Estimate
Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly sales of $74.300 million which beat the analyst consensus estimate of $72.789 million by 2.08 percent. This is a 88.09 percent increase over sales of $39.503
Benzinga Newsdesk
Earnings Scheduled For April 30, 2026
Benzinga Insights
PRO
Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $320.000M-$345.000M vs $331.417M Est
Phathom Pharmaceuticals (NASDAQ:PHAT) affirms FY2026 sales outlook from $320.000 million-$345.000 million to $320.000 million-$345.000 million vs $331.417 million estimate.
Benzinga Newsdesk
PRO
Phathom Pharmaceuticals Q1 Adj. EPS $(0.18) Beats $(0.32) Estimate, Sales $58.301M Beat $57.028M Estimate
Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.32) by 43.75 percent. This is a 83.18 percent increase over losses of $(1.07) per
Benzinga Newsdesk
